Morphic Holding, Inc. MORF
We take great care to ensure that the data presented and summarized in this overview for Morphic Holding, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MORF
View all-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.69MShares$122 Million0.42% of portfolio
-
Wellington Management Group LLP Boston, MA4.02MShares$105 Million0.03% of portfolio
-
Black Rock Inc. New York, NY3.28MShares$85.8 Million0.0% of portfolio
-
State Street Corp Boston, MA2.67MShares$69.6 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.52MShares$65.9 Million0.01% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.38MShares$62.3 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.26MShares$59.1 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N42.21MShares$57.8 Million4.2% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V81.19MShares$31 Million0.05% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.06MShares$27.7 Million0.07% of portfolio
Latest Institutional Activity in MORF
Top Purchases
Top Sells
About MORF
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Insider Transactions at MORF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2024
|
Bruce Rogers PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
7,400
+4.7%
|
$29,600
$4.32 P/Share
|
|
Jan 16
2024
|
William De Vaul General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
4,509
-16.37%
|
$121,743
$27.49 P/Share
|
|
Jan 16
2024
|
Robert E Farrell Jr SVP Finance and CAO |
SELL
Open market or private sale
|
Direct |
5,089
-12.7%
|
$137,403
$27.49 P/Share
|
|
Jan 16
2024
|
Bruce Rogers PRESIDENT |
SELL
Open market or private sale
|
Direct |
6,314
-4.26%
|
$170,478
$27.49 P/Share
|
|
Jan 16
2024
|
Marc Schegerin CFO and COO |
SELL
Open market or private sale
|
Direct |
6,041
-13.89%
|
$163,107
$27.49 P/Share
|
|
Jan 16
2024
|
Praveen P. Tipirneni CEO |
SELL
Open market or private sale
|
Direct |
13,923
-24.89%
|
$375,921
$27.49 P/Share
|
|
Jan 14
2024
|
William De Vaul General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+10.56%
|
-
|
|
Jan 14
2024
|
Robert E Farrell Jr SVP Finance and CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,470
+7.97%
|
-
|
|
Jan 14
2024
|
Bruce Rogers PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
5,070
+3.3%
|
-
|
|
Jan 14
2024
|
Marc Schegerin CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,690
+9.73%
|
-
|
|
Jan 14
2024
|
Praveen P. Tipirneni CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+18.27%
|
-
|
|
Jan 13
2024
|
William De Vaul General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
10,950
+31.07%
|
-
|
|
Jan 13
2024
|
Robert E Farrell Jr SVP Finance and CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,675
+25.72%
|
-
|
|
Jan 13
2024
|
Bruce Rogers PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
15,225
+9.61%
|
-
|
|
Jan 13
2024
|
Marc Schegerin CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,675
+27.44%
|
-
|
|
Jan 13
2024
|
Praveen P. Tipirneni CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,500
+40.45%
|
-
|
|
Nov 13
2023
|
Martin Edwards |
BUY
Open market or private purchase
|
Direct |
2,376
+50.0%
|
$47,520
$20.54 P/Share
|
|
Nov 13
2023
|
Joseph P Slattery |
BUY
Open market or private purchase
|
Direct |
2,400
+20.93%
|
$48,000
$20.6 P/Share
|
|
Sep 07
2023
|
Marc Schegerin CFO and COO |
SELL
Open market or private sale
|
Direct |
20,000
-25.35%
|
$1,080,000
$54.06 P/Share
|
|
Sep 07
2023
|
Marc Schegerin CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+31.18%
|
$300,000
$15.0 P/Share
|
Last 12 Months Summary
| Other acquisition or disposition | 1.94K shares |
|---|---|
| Open market or private purchase | 4.78K shares |
| Exercise of conversion of derivative security | 147K shares |
| Other acquisition or disposition | 101K shares |
|---|---|
| Bona fide gift | 5K shares |
| Open market or private sale | 63.1K shares |